Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Faculty of Pharmacy, National Yang-Ming University, Taipei, Taiwan, ROC.
J Chin Med Assoc. 2020 Jun;83(6):534-536. doi: 10.1097/JCMA.0000000000000318.
The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.
新型冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒 2 引起的新发传染病，目前仍在全球范围内持续蔓延。具有明确疗效的治疗或预防人类冠状病毒感染的药物或疫苗亟待开发，目前正在全球范围内大力研究。本综述总结了目前在研的有治疗潜力的药物，如洛匹那韦/利托那韦、瑞德西韦、法匹拉韦、氯喹、羟氯喹、干扰素、利巴韦林、托珠单抗、沙利鲁单抗等。目前正在开展更多的临床试验，以进一步确认这些药物治疗 COVID-19 的疗效和安全性。
